Data / Drug companies / Amneal Pharmaceuticals NY LLC
Amneal Pharmaceuticals NY LLC: 110 products in the FDA NDC directory, labeler code 60219
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Amneal Pharmaceuticals NY LLC (labeler code 60219) lists 110 products in the FDA National Drug Code Directory, covering 48 finished drugs by generic name. By type: 109 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 15, 2026.
The request: Watch Amneal Pharmaceuticals NY LLC (FDA labeler code 60219): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 60219
- Products in commercial distribution
- 110
- Packages
- 158
- Finished drugs by generic name
- 48
- Prescription products
- 109
- Over the counter products
- 1
- Controlled substance products
- Schedule IV 2, Schedule V 8
- Flagged as original packager
- 99 of 99 products that carry the flag
- Started marketing in the last 12 months
- 8
- Earliest marketing start
- May 1, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 110 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 109 | 99.1% |
| Over the counter drugs | 1 | 0.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 29 | 26.4% |
| Tablet | 22 | 20% |
| Tablet, film coated | 20 | 18.2% |
| Suspension/ drops | 9 | 8.2% |
| Solution/ drops | 8 | 7.3% |
| Tablet, extended release | 4 | 3.6% |
| Injection, suspension | 3 | 2.7% |
| Powder, for suspension | 3 | 2.7% |
| Tablet, for suspension | 3 | 2.7% |
| For solution | 2 | 1.8% |
| Suspension | 2 | 1.8% |
| Kit | 1 | 0.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Eltrombopag Olamine | 60219-1417 | Tablet, film coated | Generic drugs (ANDA) | January 15, 2026 |
| Eltrombopag Olamine | 60219-1416 | Tablet, film coated | Generic drugs (ANDA) | January 15, 2026 |
| Eltrombopag Olamine | 60219-1415 | Tablet, film coated | Generic drugs (ANDA) | January 15, 2026 |
| Eltrombopag Olamine | 60219-1414 | Tablet, film coated | Generic drugs (ANDA) | January 15, 2026 |
| Deflazacort | 60219-2285 | Tablet | Generic drugs (ANDA) | December 12, 2025 |
| Deflazacort | 60219-2284 | Tablet | Generic drugs (ANDA) | December 12, 2025 |
| Deflazacort | 60219-2283 | Tablet | Generic drugs (ANDA) | December 12, 2025 |
| Deflazacort | 60219-2282 | Tablet | Generic drugs (ANDA) | December 12, 2025 |
| Neomycin and polymyxin b sulfates and hydrocortisone | 60219-2083 | Solution/ drops | Generic drugs (ANDA) | October 29, 2025 |
| Neomycin and polymyxin b sulfates and hydrocortisone | 60219-2084 | Suspension/ drops | Generic drugs (ANDA) | September 30, 2025 |
| Bimatoprost | 60219-2149 | Solution/ drops | Generic drugs (ANDA) | September 22, 2025 |
| Pilocarpine Hydrochloride Ophthalmic | 60219-2649 | Solution/ drops | Generic drugs (ANDA) | September 1, 2025 |
| Prednisolone acetate | 60219-2552 | Suspension/ drops | Generic drugs (ANDA) | June 13, 2025 |
| Prednisolone acetate | 60219-2551 | Suspension/ drops | Generic drugs (ANDA) | June 13, 2025 |
| Prednisolone acetate | 60219-2550 | Suspension/ drops | Generic drugs (ANDA) | June 13, 2025 |
| Medroxyprogesterone Acetate | 60219-1467 | Injection, suspension | Generic drugs (ANDA) | June 10, 2025 |
| Loteprednol etabonate | 60219-1362 | Suspension/ drops | Generic drugs (ANDA) | May 22, 2025 |
| Pilocarpine Hydrochloride Ophthalmic | 60219-2366 | Solution/ drops | Generic drugs (ANDA) | May 1, 2025 |
| Lenalidomide | 60219-1719 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Lenalidomide | 60219-1718 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Lenalidomide | 60219-1717 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Lenalidomide | 60219-1716 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Lenalidomide | 60219-1715 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Lenalidomide | 60219-1714 | Capsule | Generic drugs (ANDA) | February 12, 2025 |
| Everolimus | 60219-2281 | Tablet, for suspension | Generic drugs (ANDA) | January 14, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.